Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Adaptimmune Therapeutics ( (ADAP) ).
On July 27, 2025, Adaptimmune Therapeutics entered into an agreement to sell its cell therapy assets, including TECELRA, lete-cel, afami-cel, and uza-cel, to US WorldMeds for $55 million, with potential additional payments of up to $30 million based on milestone achievements. This transaction is part of a broader restructuring plan by Adaptimmune to maximize value from its remaining assets and involves significant workforce reductions. The restructuring will see key executives depart and is expected to incur pre-tax costs of approximately $7-8 million. The transaction aims to ensure the continued availability of TECELRA to patients and support the development of other therapies by US WorldMeds.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Spark’s Take on ADAP Stock
According to Spark, TipRanks’ AI Analyst, ADAP is a Neutral.
The overall stock score reflects substantial financial risks due to persistent losses and negative equity. Despite strong operational achievements and revenue growth potential highlighted in the earnings call, financial instability and a negative valuation weigh heavily on the score. Technical analysis provides mixed signals with short-term risks of price correction.
To see Spark’s full report on ADAP stock, click here.
More about Adaptimmune Therapeutics
Adaptimmune Therapeutics is a biotechnology company focused on redefining the treatment of solid tumor cancers through cell therapy. The company is known for its engineered TCR T-cell therapies, including TECELRA, and is engaged in developing treatments for various cancer types.
Average Trading Volume: 1,005,847
Technical Sentiment Signal: Sell
Current Market Cap: $89.45M
For detailed information about ADAP stock, go to TipRanks’ Stock Analysis page.